Autonomix Medical, Inc. filed a Form 8-K on November 3, 2026, reporting the voting results of its October 29, 2026 annual meeting of stockholders and the approval of amendments to its 2023 Stock Plan.

Key Highlights

  • Quorum achieved: 905,610 shares voted, representing approximately 46% of the 1,959,938 shares outstanding as of the September 8, 2026 record date.
  • Six directors elected: Walter V. Klemp, Lori Bisson, Jonathan P. Foster, David Robins, Christopher Capelli, and Sandra Kalter, each to serve until the 2027 annual meeting.
  • Auditor ratified: Forvis Mazars, LLP was ratified as independent registered public accounting firm for the year ending March 31, 2027, with 870,562 votes for and 33,692 against.
  • Reverse stock split authorized: Stockholders approved a Board authority to effect a reverse stock split at a ratio of between 1-for-2 to 1-for-25, prior to the one-year anniversary of the Annual Meeting.
  • Stock plan expanded: Stockholders approved an increase of 750,000 shares authorized under the 2023 Stock Plan, bringing the total shares that may be issued under the plan to 750,353 shares.

Autonomix Medical 2026 Annual Meeting Results and Stock Plan Amendment Details

According to the filing, Autonomix Medical, Inc. (NASDAQ:AMIX) held its 2026 annual meeting of stockholders on October 29, 2026. The company disclosed that 905,610 shares of common stock were voted, representing approximately 46% of the 1,959,938 shares outstanding as of the September 8, 2026 record date, which the filing states constituted a quorum to transact business.

All four proposals submitted to stockholders were approved, the filing reported. For the election of directors, votes cast for each nominee ranged from 258,687 (Sandra Kalter) to 261,065 (Lori Bisson), with broker non-votes of 634,392 or 634,391 recorded for each nominee. The ratification of Forvis Mazars, LLP as independent auditor received 870,562 votes for and 33,692 against, with 1,355 abstentions and no broker non-votes. The reverse stock split proposal, which grants the Board authority to effect a split at any whole-number ratio between 1-for-2 and 1-for-25 prior to the one-year anniversary of the Annual Meeting, passed with 775,257 votes for, 110,036 against, and 20,313 abstentions.

The filing also disclosed under Item 5.02 that stockholders approved amendments to the company's 2023 Stock Plan, including an increase of 750,000 shares authorized for issuance. As amended, the company disclosed that the total number of shares of common stock that may be issued under the 2023 Plan is 750,353 shares. The filing noted that the description of the amendments "does not purport to be complete" and is qualified by reference to the full text of the amended plan, filed as Exhibit 10.1. The company's Definitive Proxy Statement, filed with the SEC on September 14, 2026, is cited for additional detail on each proposal.

What Was Disclosed

Autonomix Medical reported the final voting results of its October 29, 2026 annual stockholder meeting, covering director elections, auditor ratification, a reverse stock split authorization, and approval of an amended 2023 Stock Plan adding 750,000 authorized shares.